Pre-made Faricimab benchmark antibody ( Bispecific mAb, anti-VEGFA;ANGPT2 therapeutic antibody, Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Faricimab (INN) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.
| Products Name (INN Index) | Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody |
|---|---|
| INN Name | Faricimab |
| Target | VEGFA,ANGPT2 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | 1cz8:HL:YX;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | 1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Chugai Pharmaceutical,Roche |
| Conditions Approved | NA |
| Conditions Active | Diabetic macular oedema,Wet age-related macular degeneration,Retinal oedema |
| Conditions Discontinued | NA |
| Development Tech | Dual-Affinity?Re-targenting (DART?) |
| Previous Name | NA |
| Gm Offical Target Name | VEGFA,ANGPT2 |
| Package |
